US Imposes 100% Tariff on Patented Pharmaceuticals
The United States announced a 100% tariff on the import of patented pharmaceuticals and associated ingredients, effective from July 31. This decision stems from concerns about the nation's heavy reliance on imports, which might limit access to life-saving medications during global supply chain disruptions.
Key Points
- Exemption on Generics: The new tariffs do not currently include generic drugs. However, adjustments might be considered within a year.
- Impact on India: India primarily exports generic pharma products, which are exempt from these tariffs. The US is a major market for Indian pharmaceutical exports, holding a 40% share.
- Current Export Statistics:
- In 2025, India exported $9.7 billion worth of pharmaceuticals to the US, accounting for 38% of its global exports.
- Sun Pharma is noted for its significant sales of patented products in the US, contributing 85-90% of its global $1,217 million sales in FY25.
- Production Linked Incentive Scheme: India is promoting the manufacturing of patented drugs under this scheme, focusing on biopharmaceuticals, complex generics, gene therapy, and orphan drugs.
Implications
- Potential Tariff Impact: While the immediate impact on India is limited due to the focus on generics, there is concern about future tariffs on generics.
- Strategic Use of Tariffs: Experts suggest tariffs are a pressure tool to encourage drugmakers to reduce prices, relocate manufacturing to the US, and secure supply chains, akin to strategies used in the semiconductor industry.
